Pharmaceutical - Pharmaceutical, North America, Almirall


Almirall sets up new affiliate to support Canadian product launches


Spain's largest pharma company, Almirall (ALM: MC) has continued its expansion with the launch of a new…

AlmirallManagementMarkets & MarketingNorth AmericaPharmaceuticalTudorza Genuair

Forest Labs and Almirall opt to delay US filing for combo COPD drug


USA-based Forest Laboratories (NYSE: FRX) and Spain's largest drugmaker Almirall (ALM:MC) said late yesterday…

aclidiniumAlmirallForest LaboratoriesformoterolNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

EMA backs Almirall's Constella; Bayer's Eylea recommended by CHMP


The European Medicines Agency last Friday issued a batch of recommendations relating to marketing authorization…

AlmirallBayerConstellaEuropeEyleaGastro-intestinalsIronwood PharmaceuticalsNorth AmericaOphthalmicsPharmaceuticalRegeneronRegulation

Almirall sets up first direct North America presence


Almirall (ALM: MC), Spain's largest pharmaceutical company, says it has set up a new affiliate in Canada…

aclidiniumAlmirallMarkets & MarketingNorth AmericaPharmaceuticalRespiratory and Pulmonary

US FDA backs Forest and Almirall's Tudorza Pressair to treat COPD


US drugmaker Forest Laboratories (NYSE: FRX) and Spain's largest pharma firm Almirall (ALM: MC,) which…

AlmirallForest LaboratoriesNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

News briefs: Copaxone patent ruling; German Sativex backing; Depomed licenses Zipsor


The US District Court for the Southern District of New York has found in favor of Israel's Teva Pharmaceutical…

AlmirallAnti-Arthritics/RheumaticsCopaxoneDepomedEuropeGenericsGW PharmaceuticalsLegalLicensingMomenta PharmaceuticalsNatco PharmaNeurologicalNorth AmericaNovartisPatentsPharmaceuticalRegulationSandozSativexTeva Pharmaceutical IndustriesXanodyne PharmaceuticalsZipsor

US FDA delays approval of Almirall and Forest Laboratories' COPD drug


The US Food and Drug Administration has said it will require a three-month extension to complete its…

aclidiniumAlmirallEkliraEuropeForest LaboratoriesLicensingMenariniNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

FDA panels back Forest and Almirall COPD drug and Chelsea’s Northera for NOH


The US Food and Drug Administration’s Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 12…

aclidiniumAlmirallBiotechnologyChelsea TherapeuticsEkliraForest LaboratoriesNeurologicalNorth AmericaNortheraPharmaceuticalRegulationRespiratory and PulmonaryTudorza Pressair

Back to top